Overview
Registration
Agenda
Faculty
View Archive

Accreditation/
Credit Designation

Physicians' Education Resource®, LLC is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Physicians’ Education Resource®, LLC, designates this live activity for a maximum of 2.0 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Acknowledgment of Commercial Support

This educational activity is supported by educational grants from AstraZeneca; Genentech, Inc.; and Merck & Co., Inc.

Hepatocellular Carcinoma Tumor Board: The Experts Address Novel Regimens and Emerging Sequencing Considerations

Hepatocellular Carcinoma Tumor Board: The Experts Address Novel Regimens and Emerging Sequencing Considerations


June 25, 2020

Scientific Session: 2:00 PM – 4:00 PM EDT

Location:
Virtual Platform

Overview

A number of emerging strategies under clinical trial evaluation have recently demonstrated improved outcomes in multiple treatment settings in patients with hepatocellular carcinoma (HCC), including in resectable and previously treated unresectable disease. Genetic alterations have provided the rationale for targeted therapies in HCC, such as angiogenesis inhibitors, antimetabolites, tyrosine kinase inhibitors, and immune checkpoint inhibitors. The increasing number of treatment options for localized disease and advanced HCC has also challenged health care professionals (HCPs) to keep up with an ever-expanding armamentarium in the field. HCPs must contextualize and apply new evidence to inform individualized decision-making at key decision points in the care of their patients. The evolution of the field has raised many questions about the optimal selection, sequencing, dosing, and the combination of these treatment strategies.

Hepatocellular Carcinoma Tumor Board: The Experts Address Novel Regimens and Emerging Sequencing Considerations is a virtual symposium that will provide insights from experts on the topic of HCC tumors in the form of multidisciplinary case discussions. This activity will help HCPs maintain a state-of-the-art clinical practice by providing updates on the latest clinical data on novel therapies in HCC and offering expert guidance on sequencing therapies and optimizing multidisciplinary management of HCC.

Benefits of Attending

  • Learn from the experts about how they handle challenging clinical cases using multidisciplinary teams and how they optimize sequencing of therapies in HCC
  • Improve your knowledge about HCC biology and biomarkers in the context of how they have informed rational drug development
  • Learn about the latest clinical trial data regarding the safety and efficacy of current and emerging agents for the treatment of HCC
  • Gain expert perspectives on best practices for mitigating adverse events related to novel therapies for HCC

Acknowledgement of Commercial Support

This educational activity is supported by educational grants from AstraZeneca; Genentech, Inc.; and Merck & Co., Inc.

Target Audience: HCPs Who Treat HCC

This educational program is directed toward medical, surgical, and radiation oncologists interested in the treatment of HCC. Hepatologists, gastroenterologists, nurse practitioners, physician assistants, nurses, and other HCPs involved in the treatment and management of patients with HCC are also invited to participate.

Learning Objectives

Upon completion of this activity, participants will be able to:

  • Describe HCC biology and biomarkers in the context of how they have informed rational drug development and clinical decision-making in the HCC setting.
  • Evaluate recently reported clinical trial data regarding the safety and efficacy of current and emerging agents for the treatment of HCC
  • Identify strategies to optimize therapeutic sequencing in the treatment of HCC based on the best available evidence
  • Integrate emerging data into the context of clinical scenarios to optimize effective and safe multidisciplinary management of HCC along the treatment continuum

Program Chair

R. Kate (Katie) Kelley, MD
R. Kate (Katie) Kelley, MD
Associate Professor of Clinical Medicine
Department of Medicine (Hematology/Oncology), University of California San Francisco
San Francisco, CA

Registration

2 Ways to Register
  1. Online: click here.
  2. Phone: Please call (888) 949-0045 or (609) 378-3701.
Physicians' Education Resource®
2 Clarke Drive
Suite 110
Cranbury, NJ 08512
 
Registration Fee - Free

For registration assistance, please email info@gotoper.com, or call (888) 949-0045 or (609) 378-3701.

Physicians' Education Resource®, LLC (PER®) fully complies with the legal requirements of the ADA and the rules and regulations thereof. If any participant in this educational activity is in need of accommodations, please notify us in order to receive service. Please call (609) 378-3701.

Physicians' Education Resource®, LLC reserves the exclusive rights to all recordings or reproductions of the conference and supporting materials. Unauthorized recording, by any means, is expressly prohibited.  This includes, but is not limited to, recording of presentations or reproductions of supporting audio/visual materials, exhibits, and other supporting Continuing Education materials.

By attending a PER® conference, meeting or related activity ("Events"), all participants, attendees, exhibitors, sponsors, and guests ("you") create an agreement between you and PER® regarding the use and distribution of your image, including but not limited to your name, voice, and likeness ("Image"). By attending the Events, you acknowledge and agree that photographs, video, and/or audio recordings may be taken of you and you grant permission to PER® (and its agents) to utilize, in perpetuity, your Image in any electronic or print distribution, or by other means hereinafter created, both now and in the future, for any lawful purpose as determined by PER®.

Meeting information is accurate at the time of posting.

PER® complies with the Physician Payments Sunshine Act as a part of the Affordable Care Act (ACA). Accordingly, we may be required to collect information on transfers of value provided to any covered recipient under the ACA.



Register

You must be logged in to PER to register for this meeting

Or Register for PER now

*Required Fields

Login Information


Registration Information


Professional Information


Specialties*

Submit
Calendar of Events
SUNMONTUESWEDTHURSFRISAT
 123456
78910111213
14151617181920
21222324252627
282930
Filter By